RT Journal Article
SR Electronic
T1 Rituximab Treatment for Spondyloarthritis. A Nationwide Series: Data from the AIR Registry of the French Society of Rheumatology
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 2327
OP 2331
DO 10.3899/jrheum.120201
VO 39
IS 12
A1 DANIEL WENDLING
A1 MAXIME DOUGADOS
A1 FRANCIS BERENBAUM
A1 OLIVIER BROCQ
A1 THIERRY SCHAEVERBEKE
A1 BERNARD MAZIERES
A1 CHRISTIAN MARCELLI
A1 JEAN-MARIE LePARC
A1 PHILIPPE BERTIN
A1 MICHÈLE ROBIN
A1 JEAN SIBILIA
A1 PIERRE LAFFORGUE
A1 CLÉMENT PRATI
A1 BERNARD COMBE
A1 JACQUES-ERIC GOTTENBERG
YR 2012
UL http://www.jrheum.org/content/39/12/2327.abstract
AB Objective. To evaluate the efficacy and safety of rituximab (RTX) in several subsets of spondyloarthritis (SpA) using the data of the AIR (Autoimmunity and Rituximab) registry. Methods. All patients receiving RTX for SpA, and prospectively included in the AIR registry from September 2005 to September 2010, were retrospectively analyzed. The response to treatment was evaluated by the Bath Ankylosing Spondylitis Disease Activity Index for axial disease, joint count for peripheral disease, and C-reactive protein reduction. Results. Among the 595 patients included in the AIR registry, 26 patients with SpA from 13 centers were reported: ankylosing spondylitis (10), undifferentiated SpA (7), and psoriatic arthritis (9). Mean disease duration was 8.8 years (range 1−40). The extraarticular features found were psoriasis, 12 cases; uveitis, 4 cases; and Crohn’s disease, 3 cases. The mean number of disease-modifying antirheumatic drugs before RTX was 2.4; previous anti-tumor necrosis factor (TNF) agents were taken in 23 cases. The mean number of RTX courses was 1.5 (range 1−5), with a total of 35.6 patient-years. Efficacy was noted in 11/23 cases: 3 out of 3 anti-TNF-naive patients and 8 out of 20 anti-TNF nonresponder patients. No predictive factors of response could be identified, particularly in diagnosis subsets or clinical presentation (axial or peripheral). Conclusion. In this nationwide study of several subsets of SpA, RTX had only a moderate efficacy that was more marked in patients who were anti-TNF-naive.